JPMorgan has upgraded Envista Holdings Corp. to Overweight from Neutral, raising its price target to $32 from $29 as the dental technology group demonstrates stronger execution.
The upgrade follows second-quarter results that exceeded expectations, with adjusted earnings of $0.41 per share versus a $0.34 per share consensus and revenue of $730.5 million against a $716.61 million estimate. Envista also raised its full-year guidance after the report.
JPMorgan now projects mid-term core growth in the 2.5–4.5% range, modestly above the prior 2–4% framework. The bank expects management to outline this updated outlook at the company’s investor day on September 17.
Envista’s shares have gained 35% over the past year and 26% year-to-date, trading at $27.39 at Wednesday’s close. The stock was indicated up 2.82% in after-hours trading at $28.25. A PEG ratio of 0.55 further supports the valuation upgrade.
Eleven analysts have revised earnings estimates upward for the upcoming period, reflecting improving sentiment. CEO Paul Keel received a base salary increase to $1.3 million annually alongside a one-time equity award valued at $10 million, comprising time-based and performance-based restricted stock units.
